KYNB on Nasdaq

KYNTRA BIO, INC.

Pharmaceutical preparations company, listed on Nasdaq (KYNB). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Korro Bio, Inc., Heat Biologics or Immunome Inc., or pick any stock.

  • TickerKYNB on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Francisco, California1
  • Business address350 Bay Street, Suite 100 #6009, San Francisco, Ca 941332
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-712.7%Operating margin4
2848.6%Net margin4
-78.3%Revenue growth, 20254
-$4.8MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Drug Product Revenue brought in 91% of the revenue KYNTRA BIO, INC. broke down this way in fiscal 2025.

  1. Drug Product Revenue$5.8M491%down 79% from 2024
  2. Other Revenue - Contract Manufacturing$592.0K49%down 70% from 2024
Products and services by year
Products and services20242025
Drug Product Revenue$27.7M$5.8M
Other Revenue - Contract Manufacturing$1.9M$592.0K

Regions

Europe brought in 88% of the revenue KYNTRA BIO, INC. broke down this way in fiscal 2025.

  1. Europe$5.6M488%down 10% from 2024
  2. Japan$797.0K412%up 128% from 2024
Regions by year
Regions20242025
Europe$6.3M$5.6M
Japan-$2.9M$797.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue0¢$556.0K
  • Research and development10¢$23.5M
  • Selling, general and admin11¢$27.7M
  • Interest4¢$8.8M
  • Income tax0¢$90.0K
  • Profit75¢$183.5M

Out of $6.4M in revenue.4

Financial statements

Revenue56784$6.4M in 2025−97% since 2019
0$100.0M$200.0M$300.0M2019: $256.6M$256.6M20192020: $176.3M$176.3M2020−31%2021: $235.3M$235.3M2021+33%2022: $140.7M$140.7M2022−40%2023: $46.8M$46.8M2023−67%2024: $29.6M$29.6M2024−37%2025: $6.4M$6.4M2025−78%
Operating income56784-$45.9M in 2025−49% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$89.3M-$89.3M20192020: -$191.9M-$191.9M2020+115%2021: -$288.5M-$288.5M2021+50%2022: -$301.0M-$301.0M2022+4%2023: -$322.7M-$322.7M2023+7%2024: -$150.4M-$150.4M2024−53%2025: -$45.9M-$45.9M2025−69%
Net income56784$183.5M in 2025
-$400.0M-$200.0M0$200.0M2019: -$77.0M-$77.0M20192020: -$189.3M-$189.3M2020+146%2021: -$290.0M-$290.0M2021+53%2022: -$293.7M-$293.7M2022+1%2023: -$284.2M-$284.2M2023−3%2024: -$47.6M-$47.6M2024−83%2025: $183.5M$183.5M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$6.4M$29.6M
Cost of goods sold$556.0K$15.6M
Research and development$23.5M$95.7M
Selling, general and administrative$27.7M$49.3M
Restructuring charge$553.0K$19.5M
Total operating costs and expenses$52.3M$180.0M
Loss from operations-$45.9M-$150.4M
Interest expense-$8.8M-$8.2M
Loss on debt extinguishments-$6.6M$0
Interest income and other income (expenses), net$2.9M$5.3M
Total interest and other, net-$12.4M-$3.0M
Loss from continuing operations before income taxes-$58.3M-$153.4M
Benefit from income taxes-$90.0K-$269.0K
Loss from continuing operations-$58.2M-$153.1M
Income from discontinued operations, net of tax$241.7M$105.5M
Net income (loss)$183.5M-$47.6M
Loss from continuing operations per share - basic-$14-$38
Loss from continuing operations per share - diluted-$14-$38
Income from discontinued operations per share - basic$60$26
Income from discontinued operations per share - diluted$60$26
Net income (loss) per share - basic$45.37-$11.89
Net income (loss) per share - diluted$45.37-$11.89
Basic4.0M shares4.0M shares
Diluted4.0M shares4.0M shares

Compare KYNTRA BIO, INC. with another company

Leadership

Who has led KYNTRA BIO, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas B. Neff2014–2019
  2. James A. Schoeneck2019
  3. Enrique A. Conterno2020–2023
  4. Thane Wettig2023–now

President

  1. James A. Schoeneck2020

Chief financial officer

  1. Pat Controneo2014–2021
  2. Juan Graham2021–2024
  3. David Delucia2024–now
201520202025
Board members and other officers (25)

Former names

  • FIBROGEN INCAug 14, 2002 to Jan 7, 20262

Timeline

  1. Sep 8, 2023New chief executive Thane Wettig becomes CEO12
  2. Jan 8, 2020New chief executive Enrique A. Conterno becomes CEO13
  3. Sep 20, 2019New chief executive James A. Schoeneck becomes CEO14
  4. Nov 13, 2014New chief executive Thomas B. Neff becomes CEO15

Filings

342 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 62 major events, 176 insider forms, 32 large holders, 51 other. The latest 20:

  1. Oct 6, 20264 EDGAR
  2. Oct 6, 20263 EDGAR
  3. Oct 6, 20268-K EDGAR
  4. Oct 1, 20268-K EDGAR
  5. Sep 9, 20264 EDGAR
  6. Sep 9, 20264 EDGAR
  7. Aug 31, 20268-K EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 13, 202610-Q EDGAR
  10. Aug 13, 20268-K EDGAR
  11. Jun 17, 20264 EDGAR
  12. Jun 17, 20264 EDGAR
  13. Jun 17, 20264 EDGAR
  14. Jun 17, 20264 EDGAR
  15. Jun 16, 20268-K EDGAR
  16. Jun 9, 20264 EDGAR
  17. Jun 9, 20264 EDGAR
  18. Jun 9, 20268-K EDGAR
  19. May 19, 20264/A EDGAR
  20. May 18, 20264 EDGAR

The 342 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

58 open-market trades by officers, directors and large owners since October 2021: 10 buys and 48 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 14, 2026Wettig ThaneCEOBuy2,800$7.09$19.9KForm 4
May 14, 2026Wettig ThaneCEOBuy2,800$7.09$19.9KForm 4
Nov 17, 2025Wettig ThaneCEOBuy2,700$9.10$24.6KForm 4
Nov 13, 2025Wettig ThaneCEOBuy1,000$9.18$9.2KForm 4
Jun 30, 2025Schoeneck James ADirectorBuy23,567$5.07$119.5KForm 4
Mar 24, 2025Wettig ThaneCEOBuy145,000$0.35$50.8KForm 4
Mar 21, 2025Schoeneck James ADirectorBuy50,000$0.34$17.0KForm 4
Mar 20, 2025Schoeneck James ADirectorBuy250,000$0.35$87.5KForm 4
Jun 12, 2024Adib DeyaaChief Medical OfficerBuy22,123$1.17$25.9KForm 4
Mar 7, 2024Wettig ThaneCEOBuy50,000$1.91$95.5KForm 4
Sep 1, 2023Henderson Jeffrey WilliamDirectorSale2,000$1.03$2.1KForm 4
Aug 4, 2023Henderson Jeffrey WilliamDirectorSale2,000$1.91$3.8KForm 4
Jul 11, 2023Henderson Jeffrey WilliamDirectorSale2,000$2.69$5.4KForm 4
Jul 7, 2023Conterno Enrique AChief Executive OfficerSale1,880$2.80$5.3KForm 4
Jun 23, 2023Wettig ThaneCEOSale791$16.53$13.1KForm 4
Jun 14, 2023Chung ChristineSVP, CHINA OPERATIONSSale6,250$16.79$104.9KForm 4
Jun 13, 2023Chung ChristineSVP, CHINA OPERATIONSSale6,250$17.60$110.0KForm 4
Jun 9, 2023Cravatt BenjaminDirectorSale3,944$17.17$67.7KForm 4
Jun 9, 2023Brennan AoifeDirectorSale4,733$17.19$81.4KForm 4
Jun 9, 2023Blaug SuzanneDirectorSale8,520$17.20$146.6KForm 4

All 58 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC400,000$3.0M0.1%No change
Vanguard Capital Management LLC159,950$1.2M0.0%+3,343
BlackRock, Inc.84,330$636.7K0.0%−1
Geode Capital Management, LLC43,219$326.4K0.0%−2,779
HighTower Advisors, LLC39,746$300.1K0.0%+2
Two Sigma Investments, LP39,511$298.3K0.0%−10,000
Renaissance Technologies LLC27,081$204.5K0.0%−400
Vanguard Fiduciary Trust Co24,105$182.0K0.0%+163
Birchview Capital, LP22,566$170.4K0.1%No change
State Street Corp20,284$153.1K0.0%No change
UBS Group AG7,857$59.3K0.0%−19,734
Group One Trading LLC4,406$33.3K0.0%−86
Vanguard Global Advisers, LLC1,424$10.8K0.0%No change
Tower Research Capital LLC (TRC)1,113$8.4K0.0%+781
Axiom Investment Management LLC704$5.3K0.0%No change
Morgan Stanley487$3.7K0.0%−1
Harbour Investments, Inc.200$1.5K0.0%No change
National Bank Of Canada /fi/193$1.4K0.0%No change
Osaic Holdings, Inc.182$1.4K0.0%+2
SBI Securities Co., Ltd.152$1.1K0.0%No change
Royal Bank Of Canada138$1.0K0.0%+1
Acadian Asset Management LLC105,585$7950.0%No change
Bnp Paribas Financial Markets46$3470.0%−4
Gsa Capital Partners Llp15,697$1190.0%New
Jpmorgan Chase & Co12$880.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48